Compare Agilent Technologies Inc (A) vs Braze Inc (BRZE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Braze Inc — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Braze Inc trades at $23.99 (market cap $2.75B). The key difference: Agilent Technologies Inc is far larger — about 13.5× Braze Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| A | BRZE | |
|---|---|---|
Market Cap | $37.04B | $2.75B |
Sector | Health | Technology |
52-Week High | $157.20 | $36.19 |
52-Week Low | $110.24 | $15.79 |
Enterprise Value | $38.59B | $2.44B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Braze (BRZE) trades at $24.40, up 2.48% on the day, with a bullish technical outlook and strong analyst support. Revenue growth accelerated to 30% year-over-year in Q1 2027, though the company remains unprofitable with a net income margin of -15.51%. Recent news highlights AI-driven product enhancements and robust customer engagement demand, contributing to positive sentiment despite recent earnings misses relative to expectations.
The investment case hinges on sustained revenue acceleration and path to profitability, supported by a 96% buy rating from analysts and a $34.78 consensus price target. Key risks include persistent losses, competitive pressures in customer engagement software, and sensitivity to enterprise marketing budgets. Upside potential exists if AI adoption drives further growth and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
